NFIB promotes cell growth, aggressiveness, metastasis and EMT of gastric cancer through the Akt/Stat3 signaling pathway

Wu,Chuanqing; Zhu,Xiaojie; Liu,Weizhen; Ruan,Tuo; Wan,Wenze; Tao,Kaixiong

doi:10.3892/or.2018.6574

NFIB promotes cell growth, aggressiveness, metastasis and EMT of gastric cancer through the Akt/Stat3 signaling pathway

Authors:
- Chuanqing Wu
- Xiaojie Zhu
- Weizhen Liu
- Tuo Ruan
- Wenze Wan
- Kaixiong Tao
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Published online on: July 13, 2018 https://doi.org/10.3892/or.2018.6574
Pages: 1565-1573

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear factor I/B (NFIB) plays a crucial role in the progression of several types of cancers. However, its role in gastric cancer (GC) remains unclear. The present study revealed that NFIB was highly expressed in GC tissues and was positively associated with the clinicopathological features of GC patients. Downregulation of NFIB inhibited the tumor growth, migration and aggression of MKN45 and HGC27 cells in vitro. In addition, NFIB expression promoted epithelial‑mesenchymal transition (EMT), which was accompanied with decreased E‑cadherin and increased vimentin expression. Since AKT and Stat3 play an important role in EMT and tumor progression, we examined whether there is a correlation between NFIB and AKT/Stat3 signaling pathways in GC. Our results revealed that NFIB exhibits its oncogenic functions in GC development by regulating the phosphorylation of both AKT and Stat3 molecules. Knocking down the NFIB expression may enhance the phosphorylation of AKT while inhibiting the Stat3 phosphorylation, suggesting that the AKT/Stat3 signaling pathway may be the downstream target of NFIB with which it exerts its roles on GC development. These results revealed that NFIB promotes tumor growth and aggressiveness of GC. In addition, downregulation of NFIB alters the protein kinase B/signal transducers and activators of transcription 3 (AKT/Stat3) axis, which could be a potential molecular mechanism for precise target treatment of GC.

View Figures

View References

1	Uyama I, Suda K and Satoh S: Laparoscopic surgery for advanced gastric cancer: Current status and future perspectives. J Gastric Cancer. 13:19–25. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wu C, Ruan T, Liu W, Zhu X, Pan J, Lu W, Yan C, Tao K, Zhang W and Zhang C: Effect and mechanism of curcumin on EZH2-miR-101 regulatory feedback loop in multiple myeloma. Curr Pharm Des. 24:564–575. 2018. View Article : Google Scholar : PubMed/NCBI
3	Abbas M, Habib M, Naveed M, Karthik K, Dhama K, Shi M and Dingding C: The relevance of gastric cancer biomarkers in prognosis and pre- and post-chemotherapy in clinical practice. Biomed Pharmacother. 95:1082–1090. 2017. View Article : Google Scholar : PubMed/NCBI
4	Li Y, Guo G, Song J, Cai Z, Yang J, Chen Z, Wang Y, Huang Y and Gao Q: B7-H3 promotes the migration and invasion of human bladder cancer cells via the PI3K/Akt/STAT3 signaling pathway. J Cancer. 8:816–824. 2017. View Article : Google Scholar : PubMed/NCBI
5	Zhang LD, Chen L, Zhang M, Qi HJ, Chen L, Chen HF, Zhong MK, Shi XJ and Li QY: Downregulation of ERRα inhibits angiogenesis in human umbilical vein endothelial cells through regulating VEGF production and PI3K/Akt/STAT3 signaling pathway. Eur J Pharmacol. 769:167–76. 2015. View Article : Google Scholar : PubMed/NCBI
6	Baba Y, Tamura T, Satoh Y, Gotou M, Sawada H, Ebara S, Shibuya K, Soeda J and Nakamura K: Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine. Mol Oncol. 11:1065–1077. 2017. View Article : Google Scholar : PubMed/NCBI
7	Yu B, Lv X, Su L, Li J, Yu Y, Gu Q, Yan M, Zhu Z and Liu B: MiR-148a functions as a tumor suppressor by targeting CCK-BR via inactivating STAT3 and Akt in human gastric cancer. PLoS One. 11:e01589612016. View Article : Google Scholar : PubMed/NCBI
8	Chen KS, Lim JWC, Richards LJ and Bunt J: The convergent roles of the nuclear factor I transcription factors in development and cancer. Cancer Lett. 410:124–138. 2017. View Article : Google Scholar : PubMed/NCBI
9	Kim J, Geyer FC, Martelotto LG, Ng CK, Lim RS, Selenica P, Li A, Pareja F, Fusco N, Edelweiss M, et al: MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. J Pathol. 244:143–150. 2018. View Article : Google Scholar : PubMed/NCBI
10	Matuzelski E, Bunt J, Harkins D, Lim JWC, Gronostajski RM, Richards LJ, Harris L and Piper M: Transcriptional regulation of Nfix by NFIB drives astrocytic maturation within the developing spinal cord. Dev Biol. 432:286–297. 2017. View Article : Google Scholar : PubMed/NCBI
11	Wu Y, Zhang J, Hou S, Cheng Z and Yuan M: Non-small cell lung cancer: miR-30d suppresses tumor invasion and migration by directly targeting NFIB. Biotechnol Lett. 39:1827–1834. 2017. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Chen S, Zhang X, Peng J, Zhai E, He Y, Wu H, Chen C, Ma J, Wang Z and Cai S: VEGF promotes gastric cancer development by upregulating CRMP4. Oncotarget. 7:17074–17086. 2016.PubMed/NCBI
14	Wei YL, Dong HM, Xie ZF and Cai SX: Role of reactive oxygen species in hypoxia-induced non-small cell lung cancer migration. Zhonghua Yi Xue Za Zhi. 97:3174–3178. 2017.(In Chinese). PubMed/NCBI
15	Han MH, Lee DS, Jeong JW, Hong SH, Choi IW, Cha HJ, Kim S, Kim HS, Park C, Kim GY, et al: Fucoidan induces ROS-dependent apoptosis in 5637 human bladder cancer cells by downregulating telomerase activity via inactivation of the PI3K/Akt signaling pathway. Drug Dev Res. 78:37–48. 2017. View Article : Google Scholar : PubMed/NCBI
16	Le Rhun E, Bertrand N, Dumont A, Tresch E, Le Deley MC, Mailliez A, Preusser M, Weller M, Revillion F and Bonneterre J: Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. Eur J Cancer. 87:189–198. 2017. View Article : Google Scholar : PubMed/NCBI
17	Ina K and Furuta R: Complete response of metastatic gastric cancer to chemoimmunotherapy. Indian J Med Res. 146:1412017. View Article : Google Scholar : PubMed/NCBI
18	Li Z, Wang Q, Li B, Bai B and Zhao Q: Influence of enhanced recovery after surgery programs on laparoscopy-assisted gastrectomy for gastric cancer: A systematic review and meta-analysis of randomized control trials. World J Surg Oncol. 15:2072017. View Article : Google Scholar : PubMed/NCBI
19	Li Q, Li H, Jiang H, Feng Y, Cui Y, Wang Y, Ji Y, Yu Y, Li W, Xu C, et al: Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: A single-center prospective observational study. Clin Transl Oncol. 20:695–702. 2018. View Article : Google Scholar : PubMed/NCBI
20	Kawasaki K, Takeuchi D, Kaneko T, Miura S, Kamiya J, Miyahara Y, Yoshimura K and Ogata A: A case of advanced gastric cancer responding to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, leading to a pathological complete response. Gan To Kagaku Ryoho. 44:1017–1020. 2017.(In Japanese). PubMed/NCBI
21	He J, Wang X, Cai J, Wang W and Qin X: High expression of eIF3d is associated with poor prognosis in patients with gastric cancer. Cancer Manag Res. 9:539–544. 2017. View Article : Google Scholar : PubMed/NCBI
22	Sun GL, Li Z, Wang WZ, Chen Z, Zhang L, Li Q, Wei S, Li BW, Xu JH, Chen L, et al: miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway. J Gastroenterol. 2017.
23	Becker-Santos DD, Lonergan KM, Gronostajski RM and Lam WL: Nuclear factor I/B: A master regulator of cell differentiation with paradoxical roles in cancer. EBioMedicine. 22:2–9. 2017. View Article : Google Scholar : PubMed/NCBI
24	Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, et al: Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 25:1470–1475. 2011. View Article : Google Scholar : PubMed/NCBI
25	Fane ME, Chhabra Y, Hollingsworth DE, Simmons JL, Spoerri L, Oh TG, Chauhan J, Chin T, Harris L, Harvey TJ, et al: NFIB mediates BRN2 driven melanoma cell migration and invasion through regulation of EZH2 and MITF. EBioMedicine. 16:63–75. 2017. View Article : Google Scholar : PubMed/NCBI
26	Fusco N, Geyer FC, De Filippo MR, Martelotto LG, Ng CK, Piscuoglio S, Guerini-Rocco E, Schultheis AM, Fuhrmann L, Wang L, et al: Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Mod Pathol. 29:1292–1305. 2016. View Article : Google Scholar : PubMed/NCBI
27	Yoshida R, Sasaki T, Minami Y, Hibino Y, Okumura S, Sado M, Miyokawa N, Hayashi S, Kitada M and Ohsaki Y: Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. Int J Oncol. 51:1533–1540. 2017. View Article : Google Scholar : PubMed/NCBI
28	Mo D, Fang H, Niu K, Liu J, Wu M, Li S, Zhu T, Aleskandarany MA, Arora A, Lobo DN, et al: Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT-YB1-MDR1 signaling pathway. Cancer Res. 76:3057–66. 2016. View Article : Google Scholar : PubMed/NCBI
29	Ma DH, Li BS, Liu JJ, Xiao YF, Yong X, Wang SM, Wu YY, Zhu HB, Wang DX and Yang SM: miR-93-5p/IFNAR1 axis promotes gastric cancer metastasis through activating the STAT3 signaling pathway. Cancer Lett. 408:23–32. 2017. View Article : Google Scholar : PubMed/NCBI